High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus

BMC Infectious Diseases

Volumn 5, Issue , 2005, Pages

  Albuquerque, Edilma M V ^a   de Faria, Eliana C ^a   Oliveira, Helena C F ^a   Magro, Daniela O ^a   Castilho, Lucia N ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BRAZIL; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE SEVERITY; DYSLIPIDEMIA; EARLY DIAGNOSIS; FEMALE; FREDRICKSON PHENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; HYPERLIPOPROTEINEMIA TYPE 4; HYPERTRIGLYCERIDEMIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; WORLD HEALTH ORGANIZATION; CHEMICALLY INDUCED DISORDER; FAMILIAL HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERLIPOPROTEINEMIA TYPE 5; RISK FACTOR; VIRUS LOAD;

ANTI-HIV AGENTS; BRAZIL; FEMALE; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II; HYPERLIPOPROTEINEMIA TYPE III; HYPERLIPOPROTEINEMIA TYPE IV; HYPERLIPOPROTEINEMIA TYPE V; MALE; PHENOTYPE; RISK FACTORS; VIRAL LOAD;

EID: 27344444022     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-5-47     Document Type: Article

References (50)

1. Behrens G, Schmidt H, Meyer D, Stoll K Schmidt RE: Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet 1998, 351: 1958.
2. Henry K, Molroe H, Huebsch J, Hermudson J, Levine C,,Swensen L, Daley J: Severe premature coronary artery disease with protease inhibitors [letter]. Lancet 1998, 351: 1328.
3. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M: Vascular complication associated with use of HIV protease inhibitors [letter]. Lancet 1998, 351:1958-1959.
4. Vittecoq D, Esacaut L, Monsuez JJ: Vascular complication associated with use of HIV protease inhibitors [letter]. Lancet 1998, 351:1959.
5. Karmochkine M, Raguin G: Severe coronary artery disease in a Young HIV-infected man with no cardiovascular risk factor who was treated with Indinavir [letter]. AIDS 1998, 12:2499.
6. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M, Schmidt RE: Impaired glucose tolorance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13:F63-F70.
7. Jütte A. Schwenk A. Franzen C, Römer K, Diet F, Diel V, Fätkenheuer G, Salzberger B. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment. AIDS 1999, 13:1796-1797.
8. Sereger S, Bogner JR. Walli R. Loch O, Goebel FD: Hyperlipidemia under treatment with protease inhibitors. Infection 1999, 27:77-81.
9. Sullivan AK. Nelson MR: Marked hyperlipidaemia on ritonavir therapy. AIDS 1997, 11:-938-939.
10. Law M, Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Armino Monforte A. Pradier C, Morfeldt L. Calvo G, EI-Sadr W, De Wit S, Sabin CA. Lundgren JD: Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 2003,4:1-10.
11. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN: Hypertriglyceridemia in the acquired immunodeficiency syndrome. AmJ Med 1989, 86:27-31.
12. Hellerstein MK, Grunfeld C, Wu K, Christiansen M, Kaempfer S, Kletke C, Shackleton CHL: Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993, 76:559-565.
13. Constans J, Pelegrin JL, Peuchat E, Dumon MF, Pellegrin I, Sergeant C, Simonoff M, Brossard G, Barbeau P, Fleury H, Clerc M, Leng B, Conri C: Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994, 24:416-420.
14. Sposito AC, Caramelli B, Sartori AM, Ramires JAF: The lipoprotein profile in HIV infected patients. Braz J Infect Dis 1997, 1:275-283.
15. Sellmeyer DE, Grunfeld C: Endocrine and metabolic disturbances in human immunodeficiency virus infection and the Acquired Immune Deficiency Syndrome. Endocr Rev 1996, 17:518-532.
16. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S: Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999, 84:1932-1937.
17. Safrin S, Grunfeld C: Fat distribution metabolic changes in patients with HIV infection. AIDS 1999, 13:2493-2505.
18. U.S. Agency for International Development [http://www.usaid.gov/pop_health/aids/Countries/lac/brazilbrief.pdf]
19. Caramelli B, Bernoche Cysm, Sartori AMC, Sposito AC, Santos RD, Monachini MC, Strabelli T, Uip D: Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infect Dis 2001, 5:332-338.
20. Gillery P, Arthuis P, Cuperlier C, Circaud R: Rate nephelometric assay of serum lipoprotein(a). Clin Chem 1993, 39:503-508.
21. Chapman J, Estupinan J, Asheroy A, Goldfarb LG: A simple and efficient method for apolipoprotein E genotype determination. Neurology 1996, 46:1484-1485.
22. Fredrickson DS, Levy RS, Less RS: Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967, 276:273-281.
23. National Cholesterol Education Program: Executive Summary of the Third Report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult treatment Panel III). JAMA 2001, 285:2486-2497.
24. Castelli WP: The triglyceride issues: a view from Framingham. Am Heart J 1986, 112:432-437.
25. Schmidt HH, Behrens G, Genschel J, Stoll M, Dejam A, Haas R, Mans MP, Schmidt RE: Lipid evaluation in HIV-I-positive patients treated with protease inhibitors. Antivir Ther 1999, 4:163-170.
26. Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter WO: Differentiating hyperlipidaemia associated with antiretroviral therapy. AIDS 2003, 17:189-194.
27. Lenhard JM, Croom DK, Weiel JE, Winegar DA: HIV Protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000, 20:2625-2629.
28. Stein JH: Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis 2003, 45:293-304.
29. Stricker RB, Goldberg B: Fat accumulation and HIV-I protease inhibitors [letter]. Lancet 1998, 352:1392.
30. Carr A, Samaras K, Burbon S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperdipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
31. Gagnon A, Angel JB, Sorisky A: Protease inhibitors and adipocyte differentiation in cell culture [letter]. Lancet 1998, 352:1032.
32. Miserez AR, Muller PY, Spaniol V: Indinavir inhibits sterol-regulatory element-binding protein-I c-dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS 2002, 16:1587-1594.
33. Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusteria L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Di Cintio E, Martinelli C, Faggion I, Landonio S, Quirino T: Incidence of adverse reaction in HIV patients treated with protease inhibitors: A cohort study. Coordinamento Italiano Studio Allergiae Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 2000, 23:236-245.
34. Carr A, Samaras K, Chisholm DJ, Cooper DA: Pathogenesis of HIV-I protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881-1883.
35. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction, and natural course of HIV-I protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
36. Walli R, Herfort O, Michl GM, Demant T, Jäger H, Dieterle C, Bogner JR, Landgraf R, Goebel FD: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-I infected patients. AIDS 1998, 12:F167-F173.
37. Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM: Metabolic complications associated with antiretroviral therapy. Antiviral Res 2001, 51:151-177.
38. Thiébaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercié P, Valentin VD, Daucourt V: Serum triglycerides, HIV Infection, and highly active antiretroviral therapy, Aquitaine cohort, France, 1996 to 1998. Groupe d'Epidemiologie Clinique du Sida on Aquitaine (GECSA). J Acquir Immune Defic Syndr 2000, 23:261-265.
39. Grunfeld C, Pang M, Doerrler W, Shinegaga JK, Jensen P, Feingold KR: Lipids, lipoproteins, triglyceride clearance, and cytokines in Human Immunodeficiency Virus Infection and the Acquired Immunodeficiency Syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
40. Christeff N, Lortholary O, Casassus P, Thobie N, Dalle MT, Veyssier P, Guillevin L, Nunez EA: Serum lipid concentration with reference to the clinical and immunological status of HIV infected men. Ann Med Interne 1995, 146:490-495.
41. Seidlin M, Lambert JS, Dolin R, Valentine FT: Pancreatitis and pancreatic dysfunction in patients taking dideoxyinosine. AIDS 1992, 6:831-835.
42. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D: Decreased plasma concentration of HDL-cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 1994, 7:1149-1156.
43. Fernández-Miranda C, Polido F, Carrilo JL, Larumbe S, Gomez Izquierdo T, Ortuño B, Rubio R, Palacio A: Llpoprotein alterations in patients with HIV Infection: relation with cellular and humoral immune markers. Clin Chim Acta 1998, 274:63-70.
44. Grunfeld C, Kotler DP, Shinegaga JK, Doerrler W, Tierney A, Wang J, Pierson RN, Feingold KR: Circulating Interferon-α levels and hypertrigliceridemia in the Acquired Immunodeficiency Syndrome. Am J Med 1991, 90:154-162.
45. Cheng M, Chen S, Schow SR, Manchen VP, Spevak WR, Cristobal CP, Shi S, Macsata RW, Lum RT, Goldfine ID, Keck JG: In vitro and in vivo prevention of HIV protease inhibitor-induced insulin resistance by a novel small molecule insulin receptor activactor. J Cell Biochem 2004, 92:1234-1245.
46. Hommes MJ, Romjin JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP: Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991, 40:651-656.
47. Brites FD, Bonavita CD, De Geitere C, Cloës M, Delfly B, Yael MJ, Fruchart J, Wikinski RW, Castro GR: Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 2000, 152:181-192.
48. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, Mantero-Atienza E, Baum MK: Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus - I infection. Am J Med 1993, 94:515-519.
49. Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al.: Guidelines for evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613-627.
50. Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48-62.